文献速递肝胆胰外科围术期管理与 ERAS

上腹部手术史患者行微创远端胰腺切除术的结局

Outcomes of minimally invasive distal pancreatectomy in patients with a history of major upper abdominal surgery.
PubMed 文献 · Surg Endosc · 2025-09-18

这项单中心回顾性队列研究分析了2009至2020年间1713例行微创远端胰腺切除术的患者,按既往上腹部手术史分为无手术史组、次要手术史组和重大手术史组。结果显示三组在严重并发症(Clavien-Dindo III级及以上)、中转开腹、住院时间、90天死亡率和再入院率方面均无显著差异。研究表明,对于经过选择的既往上腹部手术(包括重大手术)患者,微创远端胰腺切除术安全可行。

要点

  • 既往上腹部重大手术患者行微创远端胰腺切除术,严重并发症发生率与无手术史者相当。
  • 中转开腹率在重大上腹部手术史组略高(7.0% vs 3.5%),但差异无统计学意义。
  • 住院时间、90天死亡率和再入院率在三组间具有可比性。

核心结论

  • 对于经过选择的既往上腹部手术(包括重大手术)患者,微创远端胰腺切除术安全可行,不显著增加严重并发症或中转开腹风险。

研究设计与样本

  • 单中心回顾性队列研究,纳入2009至2020年行微创远端胰腺切除术的1713例患者。
  • 按既往腹部手术史分为三组:无既往腹部手术组(n=1612)、次要上腹部手术史组(n=58)、重大上腹部手术史组(n=43)。
  • 主要和次要终点包括Clavien-Dindo III级及以上并发症、中转开腹、住院时间、90天死亡率和再入院率。

主要发现

  • 严重并发症(Clavien-Dindo III级及以上)发生率:无手术史组9.4%,次要上腹部手术史组10.3%(p=0.991),重大上腹部手术史组7.0%(p=0.792),组间无显著差异。
  • 中转开腹率:无手术史组3.5%,次要上腹部手术史组5.2%(p=0.266),重大上腹部手术史组7.0%(p=0.202),差异无统计学意义。
  • 住院时间、90天死亡率和再入院率在三组间具有可比性。

临床怎么用

  • 对于有上腹部手术史(包括重大手术)的左侧胰腺肿瘤患者,微创远端胰腺切除术可作为经过选择后的安全可行选项。
  • 术前应充分评估既往手术史对微创入路的影响,并做好中转开腹的准备。

局限性

  • 本研究为单中心回顾性队列研究,存在选择偏倚可能。
  • 既往上腹部手术史亚组样本量较小(次要手术史组58例,重大手术史组43例),统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimally invasive distal pancreatectomy (MIDP) is favored for left-sided pancreatic tumors, but its safety and feasibility in patients with prior upper abdominal surgery (PUAS), especially major PUAS, remain uncertain. METHODS: This retrospective cohort study analyzed 1713 patients undergoing MIDP at a single tertiary center from 2009 to 2020. Patients were divided into three groups: those with no prior abdominal surgery (no-PAS, n = 1612), those with minor PUAS (n = 58), and those with major PUAS (n = 43). Primary and secondary endpoints included complications of Clavien-Dindo grade III or higher, conversion to open surgery, length of hospital stay, 90-day mortality, and readmission rates. RESULTS: Among the 1713 patients who underwent MIDP, no significant differences in the rate of severe complications (Clavien-Dindo grade III or higher) were observed between the no-PAS group (9.4%) and either the minor-PUAS (10.3%, p = 0.991) or major-PUAS (7.0%, p = 0.792) groups. Conversion to open surgery occurred in 3.5% of patients in the no-PAS group, with slightly higher rates in the minor-PUAS (5.2%, p = 0.266) and major-PUAS (7.0%, p = 0.202) groups; however, these differences were not statistically significant. Length of hospital stay, 90-day mortality, and readmission rates were comparable across groups. CONCLUSION: MIDP appears to be a safe and feasible option for selected patients with PUAS, including major procedures, without significantly increasing the risks of severe complications or conversion to open surgery. These findings support the broader use of MIDP in patients with complex surgical histories.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Park Y, Hwang DW, Lee JH, et al. Outcomes of minimally invasive distal pancreatectomy in patients with a history of major upper abdominal surgery. Surg Endosc. 2025. PMID: 40968210. doi:10.1007/s00464-025-12234-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。